| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H21IN2O3 |
| Molecular Weight | 400.2444 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCC[C@H]1CNC(=O)C2=C(O)C([123I])=CC=C2OC
InChI
InChIKey=CANPFCFJURGKAX-SCBSARHOSA-N
InChI=1S/C15H21IN2O3/c1-3-18-8-4-5-10(18)9-17-15(20)13-12(21-2)7-6-11(16)14(13)19/h6-7,10,19H,3-5,8-9H2,1-2H3,(H,17,20)/t10-/m0/s1/i16-4
| Molecular Formula | C15H21IN2O3 |
| Molecular Weight | 400.2444 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
IOLOPRIDE I-123 (also known as I-123 iodobenzamide), a radioactive drug that can be seen by Single-photon emission computed tomography. This drug binds to the some dopamine receptors and can be used in the neonatal period. It shows the biochemical maturation of D2 receptors and also manifests the deleterious effect of perinatal hypoxic-ischemic events on D2 receptors.
Approval Year
PubMed
|
|
TARGET->RADIOLIGAND |
|
||
|
|
TARGET->RADIOLIGAND |
|
||
|
|
NON-LABELED -> LABELED |
|
Showing 1 to 3 of 3 entries
